Du Xue, Pi Yi, Dreyer Rachel P, Li Jing, Li Xi, Downing Nicholas S, Li Li, Feng Fang, Zhan Lijuan, Zhang Haibo, Guan Wenchi, Xu Xiao, Li Shu-Xia, Lin Zhenqiu, Masoudi Frederick A, Spertus John A, Krumholz Harlan M, Jiang Lixin
National Clinical Research Center of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China.
Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut.
Catheter Cardiovasc Interv. 2016 Dec;88(7):E212-E221. doi: 10.1002/ccd.26461. Epub 2016 Mar 4.
The number of percutaneous coronary interventions (PCI) in China has increased more than 20-fold over the last decade. Consequently, there is a need for national-level information to characterize PCI indications and long-term patient outcomes, including health status, to understand and improve evolving practice patterns.
This nationwide prospective study of patients receiving PCI is to: (1) measure long-term clinical outcomes (including death, acute myocardial infarction [AMI], and/or revascularization), patient-reported outcomes (PROs), cardiovascular risk factor control and adherence to medications for secondary prevention; (2) determine patient- and hospital-level factors associated with care process and outcomes; and (3) assess the appropriateness of PCI procedures.
The China Patient-centered Evaluative Assessment of Cardiac Events (PEACE) Prospective Study of PCI has enrolled 5,000 consecutive patients during 2012-2014 from 34 diverse hospitals across China undergoing PCI for any indication. We abstracted details of patient's medical history, treatments, and in-hospital outcomes from medical charts, and conducted baseline, 1-, 6-, and 12-month interviews to characterize patient demographics, risk factors, clinical presentation, healthcare utilization, and health status using validated PRO measures. The primary outcome, a composite measure of death, AMI and/or revascularization, as well as PROs, medication adherence and cardiovascular risk factor control, was assessed throughout the 12-month follow-up. Blood and urine samples were collected at baseline and 12 months and stored for future analyses. To validate reports of coronary anatomy, 2,000 angiograms are randomly selected and read by two independent core laboratories. Hospital characteristics regarding their facilities, processes and organizational characteristics are assessed by site surveys.
China PEACE Prospective Study of PCI will be the first study to generate novel, high-quality, comprehensive national data on patients' socio-demographic, clinical, treatment, and metabolic/genetic factors, and importantly, their long-term outcomes following PCI, including health status. This will build the foundation for PCI performance improvement efforts in China. © 2016 The Authors. Catheterization and Cardiovascular Interventions. Published by Wiley Periodicals, Inc.
在过去十年中,中国经皮冠状动脉介入治疗(PCI)的数量增长了20多倍。因此,需要国家级信息来描述PCI的适应症和患者长期预后,包括健康状况,以了解和改善不断演变的实践模式。
这项针对接受PCI治疗患者的全国性前瞻性研究旨在:(1)衡量长期临床结局(包括死亡、急性心肌梗死[AMI]和/或血运重建)、患者报告结局(PROs)、心血管危险因素控制以及二级预防药物的依从性;(2)确定与治疗过程和结局相关的患者及医院层面因素;(3)评估PCI手术的适宜性。
中国以患者为中心的心脏事件评估(PEACE)PCI前瞻性研究在2012年至2014年期间,从中国各地34家不同医院连续纳入了5000例因任何适应症接受PCI治疗的患者。我们从病历中提取了患者病史、治疗及院内结局的详细信息,并在基线、1个月、6个月和12个月时进行访谈,使用经过验证的PRO测量方法来描述患者人口统计学、危险因素、临床表现、医疗保健利用情况和健康状况。在整个12个月的随访期间,评估主要结局,即死亡、AMI和/或血运重建的综合指标,以及PROs、药物依从性和心血管危险因素控制情况。在基线和12个月时采集血液和尿液样本并储存以备将来分析。为验证冠状动脉解剖结构报告,随机选择2000份血管造影图像,由两个独立的核心实验室进行解读。通过现场调查评估医院在设施、流程和组织特征方面的特点。
中国PEACE PCI前瞻性研究将是第一项生成关于患者社会人口统计学、临床、治疗和代谢/遗传因素的新颖、高质量、全面的全国性数据的研究,重要的是,还将生成关于患者PCI术后长期结局(包括健康状况)的数据。这将为中国PCI性能改进工作奠定基础。© 2016作者。《导管插入术与心血管介入》。由威利期刊公司出版。